TW202203908A - 截短側耳素類之醫療用途 - Google Patents
截短側耳素類之醫療用途 Download PDFInfo
- Publication number
- TW202203908A TW202203908A TW110113773A TW110113773A TW202203908A TW 202203908 A TW202203908 A TW 202203908A TW 110113773 A TW110113773 A TW 110113773A TW 110113773 A TW110113773 A TW 110113773A TW 202203908 A TW202203908 A TW 202203908A
- Authority
- TW
- Taiwan
- Prior art keywords
- hydroxy
- mutilin
- acetyl
- cyclohexylthio
- compound
- Prior art date
Links
- 0 CC(C1CC2)C3*1C2(C)*C1C3C1 Chemical compound CC(C1CC2)C3*1C2(C)*C1C3C1 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/16—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011474P | 2020-04-17 | 2020-04-17 | |
| EP20170072.1 | 2020-04-17 | ||
| US63/011,474 | 2020-04-17 | ||
| EP20170072 | 2020-04-17 | ||
| EP20183292.0 | 2020-06-30 | ||
| EP20183292 | 2020-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202203908A true TW202203908A (zh) | 2022-02-01 |
Family
ID=75801547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110113773A TW202203908A (zh) | 2020-04-17 | 2021-04-16 | 截短側耳素類之醫療用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230174472A1 (https=) |
| EP (1) | EP4135682A1 (https=) |
| JP (2) | JP2023522644A (https=) |
| CN (1) | CN115443131A (https=) |
| BR (1) | BR112022020007A2 (https=) |
| CA (1) | CA3180535A1 (https=) |
| IL (1) | IL297268A (https=) |
| TW (1) | TW202203908A (https=) |
| WO (1) | WO2021209174A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250134844A1 (en) | 2022-02-09 | 2025-05-01 | Nabriva Therapeutics GmbH | Therapeutic use of pleuromutilins |
| EP4338732A1 (en) | 2022-09-16 | 2024-03-20 | Nabriva Therapeutics GMBH | Lefamulin and its derivatives for use in the treatment of tularemia |
| CN119925362A (zh) * | 2023-11-03 | 2025-05-06 | 阳光安津(南京)生物医药科技有限公司 | 一种化合物在制备用于治疗银屑病的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298733B1 (en) * | 2005-06-27 | 2016-05-25 | Nabriva Therapeutics AG | Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group |
| EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| GB0803707D0 (en) | 2008-02-28 | 2008-04-09 | Cambridge Entpr Ltd | Antiviral agent |
| EP2399904A1 (en) * | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
| CN103204787B (zh) | 2012-01-17 | 2014-10-01 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| CN103242210B (zh) | 2012-02-09 | 2014-09-24 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| KR102656841B1 (ko) | 2015-06-17 | 2024-04-12 | 나브리바 테라퓨틱스 게엠베하 | 레파뮬린의 주사가능한 약제학적 제형 |
| CN110507823B (zh) * | 2019-08-20 | 2021-08-24 | 中国医学科学院基础医学研究所 | 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用 |
-
2021
- 2021-04-16 CN CN202180028994.6A patent/CN115443131A/zh active Pending
- 2021-04-16 IL IL297268A patent/IL297268A/en unknown
- 2021-04-16 TW TW110113773A patent/TW202203908A/zh unknown
- 2021-04-16 US US17/919,200 patent/US20230174472A1/en active Pending
- 2021-04-16 BR BR112022020007A patent/BR112022020007A2/pt not_active Application Discontinuation
- 2021-04-16 JP JP2022562465A patent/JP2023522644A/ja active Pending
- 2021-04-16 EP EP21723641.3A patent/EP4135682A1/en active Pending
- 2021-04-16 WO PCT/EP2021/025140 patent/WO2021209174A1/en not_active Ceased
- 2021-04-16 CA CA3180535A patent/CA3180535A1/en active Pending
-
2025
- 2025-12-04 JP JP2025230606A patent/JP2026041886A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3180535A1 (en) | 2021-10-21 |
| JP2023522644A (ja) | 2023-05-31 |
| IL297268A (en) | 2022-12-01 |
| BR112022020007A2 (pt) | 2022-11-22 |
| WO2021209174A1 (en) | 2021-10-21 |
| EP4135682A1 (en) | 2023-02-22 |
| US20230174472A1 (en) | 2023-06-08 |
| CN115443131A (zh) | 2022-12-06 |
| JP2026041886A (ja) | 2026-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041886A (ja) | プレウロムチリンの治療的使用 | |
| EP4135683B1 (en) | Antiviral use of pleuromutilins | |
| KR102747437B1 (ko) | 최적화된 화합물 | |
| CN115836079B (zh) | 烟酰胺单核苷酸和烟酰胺核苷衍生物及其在治疗特别是由流感病毒或冠状病毒引起的病毒感染和呼吸道并发症中的用途 | |
| KR20150013527A (ko) | 항염증 활성과 접합된 증진된 항인플루엔자제 | |
| EP3556377A1 (en) | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | |
| WO2020241759A1 (ja) | インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤 | |
| US11965006B2 (en) | Antimicrobial and anti-cancer therapy | |
| EP1660059A1 (en) | Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars) | |
| JP2023520917A (ja) | 呼吸器状態を処置するためのｔｒｐｃ６阻害剤 | |
| KR20090102850A (ko) | 항바이러스 화합물 | |
| EP4135681B1 (en) | Antiviral use of pleuromutilins | |
| US20180066018A1 (en) | Conformationally stable analogs of the response selective c5a agonist ep67 | |
| MX2012005551A (es) | Tratamiento de infecciones microbianas. | |
| EP4125924B1 (en) | Furosemide compositions for use in supportive therapy in coronavirus infection | |
| EP3720440A1 (en) | Treatment of rsv with combination product | |
| JPH05310578A (ja) | ミゾリビンを有効成分とする感染疾患の予防または治療剤 | |
| WO2025231155A2 (en) | Methods for reducing or preventing sars-cov-2 infection and transmission | |
| EP4710930A1 (en) | Anti-influenza virus composition containing xanthan gum or fucoidan | |
| EP3949964A1 (en) | Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of viral infections | |
| Walker | American Thoracic Society (ATS) 2014 International Conference-San Diego, California, USA-May 16-21, 2014 |